Quote | Erasca Inc. (NASDAQ:ERAS)
Last: | $1.88 |
---|---|
Change Percent: | 1.6% |
Open: | $1.85 |
Close: | $1.88 |
High: | $1.89 |
Low: | $1.81 |
Volume: | 466,394 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Erasca Inc. (NASDAQ:ERAS)
Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer Poster presentations will feature SEACRAFT-1 Phase 1 trial design for naporafenib plus trametinib in RAS Q61X mutations, and p...
2024-03-29 11:11:07 ET Erasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Conference Call March 28, 2024, 08:30 ET Company Participants Jonathan Lim - Chairman, CEO & Co-founder Shannon Morris - Chief Medical Officer David Chacko - CFO & Chief B...
Message Board Posts | Erasca Inc. (NASDAQ:ERAS)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Erasca Inc. Company Name:
ERAS Stock Symbol:
NASDAQ Market:
Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm col...
Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer Poster presentations will feature SEACRAFT-1 Phase 1 trial design for naporafenib plus trametinib in RAS Q61X mutations, and p...
SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS) ("Erasca"), a clinical-stage precision oncology company singularly focu...